April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Developing Photoreceptor Targeted AAV Variant by Directed Evolution
Author Affiliations & Notes
  • Deniz Dalkara
    HWNI and CChem,
    Univ of California, Berkeley, Berkeley, California
  • Ryan R. Klimczak
    Univ of California, Berkeley, Berkeley, California
  • Meike Visel
    HWNI and Optometry,
    Univ of California, Berkeley, Berkeley, California
  • Natalie Hoffmann
    HWNI and Optometry,
    Univ of California, Berkeley, Berkeley, California
  • David Schaffer
    HWNI and ChemE and BioE,
    Univ of California, Berkeley, Berkeley, California
  • John Flannery
    HWNI and Optometry,
    Univ of California, Berkeley, Berkeley, California
  • Footnotes
    Commercial Relationships  Deniz Dalkara, None; Ryan R. Klimczak, None; Meike Visel, None; Natalie Hoffmann, None; David Schaffer, None; John Flannery, None
  • Footnotes
    Support  NIH grants EY016994 and 7PN2EY018241, and the Foundation for Fighting Blindness
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4381. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deniz Dalkara, Ryan R. Klimczak, Meike Visel, Natalie Hoffmann, David Schaffer, John Flannery; Developing Photoreceptor Targeted AAV Variant by Directed Evolution. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4381.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The majority of mutations causing retinal degeneration are found in photoreceptor (PR) -specific genes. Gene therapy has great potential for treating PR diseases; however, to date all vectors that are able to target these cells require subretinal (SR) administration. SR injection of AAV vector is impractical for many patients with retinal degenerations, in which random, scattered islands of surviving PRs render selection of an ideal injection site difficult. The aim of our study is to apply a directed evolutionary approach to create AAV variants capable of transducing large numbers of PRs via a safe, intravitreal injection.

Methods: : Three viral libraries were employed in this study: a random mutagenesis library of the AAV2 cap gene, a shuffled library composed of chimeric AAV cap genes from serotypes 1-9, and a 7mer library composed of randomized 7mers inserted near the three-fold axis of symmetry on the AAV2 capsid. These libraries were mixed together and injected into mice eyes expressing a rhodopsin-GFP fusion in their PRs. The PRs were then sorted by flow cytometry and successful variants were chosen through multiple iterations and subjected to a further round of error-prone PCR to create a successive generation of permissive variants. After multiple generations, variants from the resulting pool were analyzed to elucidate PR permissive mutations by cloning these variants into recombinant form and packaging them with a GFP transgene to assay PR-infectivity.

Results: : Sequence data from the final round of selections showed substantial convergence, as an initial library diversity consisting of millions resulted in a handful of variants derived from the 7mer library with 60% of the clones carrying the identical 7mer sequence. One of these variants, named 7m8 was used to package the GFP gene and was tested for retinal transduction. 7m8 led to strong, pan-retinal transgene expression in the PRs.

Conclusions: : Directed evolution is a powerful approach to manipulate the tropism of AAV vectors in the retina. The isolated variants provide us with new information on amino acid changes that allow extended diffusion in retinal tissue as well as increases in infection capacity likely resulting from improvements in binding and endocytosis. We are now testing the feasibility of a gene replacement therapy from the vitreous using our new PR permissive variant.

Keywords: gene transfer/gene therapy • retinal degenerations: hereditary • photoreceptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.